Analysis of Tumor Deposit at the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients With Gastric Cancer Who Received Proximal Gastrectomy (zypg001)

August 25, 2025 updated by: Jichao Qin

Tumor Deposit at the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients With Gastric Cancer Who Received Proximal Gastrectomy With D2 Lymphadenectomy Plus Complete Mesogastric Excision for Gastric Cancer: A Prospective Observational Study

This study aims to evaluate the tumor deposit at the fusion site of the right gastric mesentery and left gastric mesentery in the patients with gastric cancer who received proximal gastrectomy.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

In the 6th edition of the Japanese Gastric Cancer Treatment Guidelines; during proximal gastrectomy, D2 lymphadenectomy includes nodes No. 1, No. 2, No. 3a, No. 4sa, No. 4sb, No. 7, No. 8a, No. 9, No. 11p, and No. 11d. When performing D2 surgery for proximal gastric cancer, the dissection typically includes No. 3a (Lymph nodes along the branches of the left gastric artery, including those below the cardia branch) and No. 7 (distributed along the left gastric artery from its root to the bifurcation of the ascending branch), while not including the No. 5 group nodes (located in the upper region of the pylorus between the root of the right gastric artery and the first branch of the gastric wall). In D2 lymphadenectomy plus complete mesogastric excision (CME) for proximal gastric cancer, a complete resection of the left gastric mesentery is performed without removing the right gastric mesentery. However, clinical observations have shown that there may be a fusion between the left and right gastric mesenteries. Merely excising the left gastric mesentery could potentially lead to tumor residue or recurrence in the right mesentery. This study aims to investigate tumor deposit at the fusion site of the right gastric mesentery and left gastric mesentery following D2+CME surgery for proximal gastric cancer, intending to provide evidence-based medical insights for standardizing lymph node clearance in gastric cancer.

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310000
        • Recruiting
        • Department of Gastrointestinal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients undergoing proximal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision. At the same time, the patients met the above inclusion and exclusion criteria.

Description

Inclusion Criteria:

  1. Aged older than 18 years and younger than 85 years
  2. Primary gastric adenocarcinoma confirmed by preoperative pathology result
  3. cT2-4aN0-3M0 at preoperative evaluation according to the American Joint 8 Committee on Cancer (AJCC) Cancer Staging Manual 8th Edition
  4. Patients undergoing proximal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision
  5. American Society of Anesthesiologists (ASA) class I, II, or III
  6. Written informed consent

Exclusion Criteria:

  1. Negative preoperative biopsy
  2. Too late tumour stage or metastasis (cT4b/M1)
  3. BMI>30 kg/m2
  4. previous neoadjuvant chemotherapy or radiotherapy
  5. Previous upper abdominal surgery
  6. Combined with other malignant diseases
  7. Reject operation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients undergoing proximal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision
Other: In addition to routine diagnosis and treatment, no additional intervention measures were taken.
This study does not impose any intervention on the patients

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Rate of tumor deposit at the fusion site of the right gastric mesentery and left gastric mesentery; Through postoperative pathological diagnosis
Time Frame: through study completion, an average of 1 year
through study completion, an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Jichao Qin

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2024

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2027

Study Registration Dates

First Submitted

September 1, 2024

First Submitted That Met QC Criteria

December 8, 2024

First Posted (Actual)

December 11, 2024

Study Record Updates

Last Update Posted (Estimated)

September 2, 2025

Last Update Submitted That Met QC Criteria

August 25, 2025

Last Verified

August 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2024-0899-2

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gastric Carcinoma

Clinical Trials on In addition to routine diagnosis and treatment, no additional intervention measures were taken.

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe